StockData
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. (NERV) stock

NERVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$2.18+0.02 (+0.93%)

Close on Nov 18, 2026Market cap $104.09MP/E –Yield –

Minerva Neurosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Minerva Neurosciences's operating income for the twelve months ending Jun 30, 2026 was -$35.14M. For fiscal 2025 it was -$15.10M. The highest annual figure on record is $1.85M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$15.10M–
FY2024Dec 31, 2024-$21.85M–
FY2023Dec 31, 2023-$23.12M–
FY2022Dec 31, 2022-$25.23M–
FY2021Dec 31, 2021-$45.37M-2556.5%
FY2020Dec 31, 2020$1.85M–
FY2019Dec 31, 2019-$75.87M–
FY2018Dec 31, 2018-$51.73M–
FY2017Dec 31, 2017-$41.17M–
FY2016Dec 31, 2016-$30.19M–
FY2015Dec 31, 2015-$26.11M–
FY2014Dec 31, 2014-$54.87M–
FY2013Dec 31, 2013-$3.17M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$10.64M–
Q1 FY2026Mar 31, 2026-$16.67M–
Q4 FY2025Dec 31, 2025-$4.98M–
Q3 FY2025Sep 30, 2025-$2.84M–
Q2 FY2025Jun 30, 2025-$3.37M–
Q1 FY2025Mar 31, 2025-$3.90M–
Q4 FY2024Dec 31, 2024-$4.52M–
Q3 FY2024Sep 30, 2024-$4.37M–
Q2 FY2024Jun 30, 2024-$6.28M–
Q1 FY2024Mar 31, 2024-$6.68M–
Q4 FY2023Dec 31, 2023-$7.17M–
Q3 FY2023Sep 30, 2023-$6.08M–
Q2 FY2023Jun 30, 2023-$4.52M–
Q1 FY2023Mar 31, 2023-$5.35M–
Q4 FY2022Dec 31, 2022-$5.07M–
Q3 FY2022Sep 30, 2022-$5.21M–
Q2 FY2022Jun 30, 2022-$6.97M–
Q1 FY2022Mar 31, 2022-$7.99M–
Q4 FY2021Dec 31, 2021-$21.38M–
Q3 FY2021Sep 30, 2021-$7.52M–
Q2 FY2021Jun 30, 2021-$8.96M-130.4%
Q1 FY2021Mar 31, 2021-$7.51M–
Q4 FY2020Dec 31, 2020-$7.30M–
Q3 FY2020Sep 30, 2020-$8.09M–
Q2 FY2020Jun 30, 2020$29.51M–
Q1 FY2020Mar 31, 2020-$12.27M–
Q4 FY2019Dec 31, 2019-$32.37M–
Q3 FY2019Sep 30, 2019-$14.28M–
Q2 FY2019Jun 30, 2019-$12.90M–
Q1 FY2019Mar 31, 2019-$16.31M–
Q4 FY2018Dec 31, 2018-$13.63M–
Q3 FY2018Sep 30, 2018-$12.42M–
Q2 FY2018Jun 30, 2018-$12.94M–
Q1 FY2018Mar 31, 2018-$12.74M–
Q4 FY2017Dec 31, 2017-$9.53M–
Q3 FY2017Sep 30, 2017-$11.41M–
Q2 FY2017Jun 30, 2017-$9.75M–
Q1 FY2017Mar 31, 2017-$10.49M–
Q4 FY2016Dec 31, 2016-$9.24M–
Q3 FY2016Sep 30, 2016-$8.23M–

More Minerva Neurosciences figures

See a number that looks wrong?